Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT01906489 · ClinicalTrials.gov registry record · Phase 2

20-Week Repeat Oral Dose Study of AKB-6548 in Participants With Chronic Kidney Disease and Anemia

A Phase 2 study of Chronic Kidney Disease and Anemia, sponsored by Akebia Therapeutics.

Completed
Registry status
Phase 2
Development phase
210
Enrollment target
20
Study locations

NCT01906489 is a Phase 2 study of Chronic Kidney Disease and Anemia that has completed, run by Akebia Therapeutics. The registered enrollment target is 210 participants, below the 3,205-participant average among 101 other Chronic Kidney Disease trials with a reported enrollment target (93% lower). The trial reports 20 study locations across 7 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT01906489, a Phase 2 study of Chronic Kidney Disease and Anemia, has completed, sponsored by Akebia Therapeutics.

COMPLETED
Registry status
Phase 2
Development phase
210 participants
Enrollment target
20
Study locations

Study Summary

The purpose of this study is to evaluate the hemoglobin response (efficacy), safety, and tolerability of orally administered AKB-6548 in participants with Chronic Kidney Disease (pre-dialysis) with anemia with dosing for 20 weeks.

Conditions Studied

Chronic Kidney Disease Anemia

Interventions

  • DRUG Placebo
  • DRUG AKB-6548

Study Locations (20)

California

  • - Azusa
  • - Chula Vista
  • - Downey
  • - El Centro
  • - La Mesa
  • - Long Beach
  • - Riverside
  • - Sacramento
  • - San Diego

Florida

  • - Lauderdale Lakes
  • - Port Charlotte
  • - Tampa

Arizona

  • - Glendale
  • - Tucson

Colorado

  • - Arvada
  • - Westminster

Georgia

  • - Augusta
  • - Macon

Idaho

  • - Meridian

Illinois

  • - Evergreen Park

Trial Details

FieldValue
Enrollment Target 210 participants
Start Date 2013-07-23
Est. Completion 2014-09-03
Phase Phase 2

Sponsor

Akebia Therapeutics

24 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT01906489

The ClinicalTrials.gov registry entry for NCT01906489 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 210 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 3,205-participant average among 101 other Chronic Kidney Disease trials with a reported enrollment target (93% lower). The listed sponsor is Akebia Therapeutics, which has 24 total studies on file at ClinicalTrials.gov.

The record links to 2 conditions, with Chronic Kidney Disease appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.

NCT01906489 reports 20 study locations spanning 7 distinct geographic areas - top geographies include California, Florida, Arizona.

Frequently Asked Questions

What is clinical trial NCT01906489 about?

NCT01906489 is a clinical study titled "20-Week Repeat Oral Dose Study of AKB-6548 in Participants With Chronic Kidney Disease and Anemia". The purpose of this study is to evaluate the hemoglobin response (efficacy), safety, and tolerability of orally administered AKB-6548 in participants with Chronic Kidney Disease (pre-dialysis) with anemia with dosing for 20 weeks.

What is the current status of trial NCT01906489?

This trial is currently completed. It is a Phase 2 study. The enrollment target is 210 participants. The study started on 2013-07-23. Estimated completion is 2014-09-03.

What conditions does trial NCT01906489 study?

This clinical trial studies the following conditions: Chronic Kidney Disease, Anemia.

What interventions are being tested in trial NCT01906489?

The interventions under investigation include: Placebo (DRUG), AKB-6548 (DRUG).

Who is sponsoring clinical trial NCT01906489?

This trial is sponsored by Akebia Therapeutics, which has 24 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT01906489 being conducted?

This trial has 20 study locations across Arizona, California, Colorado, Florida, Georgia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Chronic Kidney Disease

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Chronic Kidney Disease

All registered trials for this condition

Anemia

All registered trials for this condition

Arizona

All trials with a study site in Arizona

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.